UAB30, a Novel RXR Agonist, Decreases Tumorigenesis and Leptomeningeal Disease in Group 3 Medulloblastoma Patient-Derived Xenografts

BACKGROUND: Group 3 tumors account for approximately 25–30% of medulloblastomas and have the worst prognosis. UAB30 is a novel synthetic rexinoid shown to have limited toxicities in humans and significant efficacy in the pediatric neuroectodermal tumor, neuroblastoma. We hypothesized that treatment...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Neurooncol
Main Authors: Garner, Evan F., Stafman, Laura L., Williams, Adele P., Aye, Jamie M., Goolsby, Caroline, Atigadda, Venkatram R., Moore, Blake P., Nan, Li, Stewart, Jerry E., Hjelmeland, Anita B., Friedman, Gregory K., Beierle, Elizabeth A.
Formato: Artigo
Idioma:Inglês
Publicado em: 2018
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6239946/
https://ncbi.nlm.nih.gov/pubmed/30132166
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s11060-018-2950-1
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados